• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Meningitis - Pipeline Review, H2 2011 - Product Image

Meningitis - Pipeline Review, H2 2011

  • Published: September 2011
  • 97 pages
  • Global Markets Direct

Meningitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Meningitis - Pipeline Review, H2 2011', provides an overview of the Meningitis therapeutic pipeline. This report provides information on the therapeutic development for Meningitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningitis. 'Meningitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Meningitis.
- A review of the Meningitis products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningitis Overview
Therapeutics Development
An Overview of Pipeline Products for Meningitis
Meningitis Therapeutics under Development by Companies
Meningitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Meningitis Therapeutics - Products under Development by Companies
Meningitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Meningitis Therapeutics Development
Baxter International Inc.
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
InterMune, Inc.
Pfizer Inc.
LG Life Sciences, Ltd
Eurocine Vaccines AB
Snowdon Inc.
Sinovac Biotech Ltd.
Cornerstone Therapeutics Inc.
Serum Institute of India Limited
Baxter Healthcare Corporation
Sanofi Pasteur MSD
Meningitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SND-159 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMGB1 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NZ98/254 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MnB rLP208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V501 + Menactra + Adacel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infanrix Hexa + Paracetamol + GSK1024850A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ceftazidime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paracetamol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glycerol + Paracetamol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nimenrix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningococcal A Conjugate Vaccine + EPI Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pemetrexed Disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Gamma-1B + Flucytosine + Amphotericin B + Fluconazole or Itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NeisVac-C Prime Boost Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bexsero - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bexsero - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daptacel + IPOL + Menactra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Group B Meningococcal 44/76 MOS NOMV 5D Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RotaTeq + NeisVac-C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptococcus pneumoniae Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasal Pneumococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMRV + Menactra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amphotericin B + Fluconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NeisVac-C + Prevenar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK 134612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Menitorix + Priorix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib (Recon) Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIB vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rMenB + MenABCWY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningitis Therapeutics – Drug Profile Updates
Meningitis Therapeutics - Discontinued Products
Meningitis - Featured News
Jun 09, 2011: Novartis's Bexsero Shows Significant Potential In Providing Broad Coverage Against Meningococcal Serogroup B Infections
Sep 12, 2010: Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Provide Broad Coverage Against Deadly Disease
May 26, 2005: The US FDA Approves New Indication For Merrem I.V for Complicated Skin and Skin Structure Infections
Aug 02, 2004: AstraZeneca Submits supplemental New Drug Application to the U.S. Food and Drug Administration for Merrem I.V for a new indication of skin and skin structure infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Meningitis, H2 2011
Products under Development for Meningitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Baxter International Inc., H2 2011
Sanofi-Aventis, H2 2011
GlaxoSmithKline plc, H2 2011
Merck & Co., Inc., H2 2011
Novartis AG, H2 2011
InterMune, Inc., H2 2011
Pfizer Inc., H2 2011
LG Life Sciences, Ltd, H2 2011
Eurocine Vaccines AB, H2 2011
Snowdon Inc., H2 2011
Sinovac Biotech Ltd., H2 2011
Cornerstone Therapeutics Inc., H2 2011
Serum Institute of India Limited, H2 2011
Baxter Healthcare Corporation, H2 2011
Sanofi Pasteur MSD, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Meningitis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Meningitis, H2 2011
Products under Development for Meningitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos